|
Ultragenyx Pharmaceutical Inc. (rare) Valation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Ultragenyx Pharmaceutical Inc. (RARE) Bundle
Gardez un aperçu de votre analyse d'évaluation (rare) Ultragenyx Pharmaceutical Inc. en utilisant notre calculatrice sophistiquée DCF! Ce modèle Excel est préchargé avec de vraies (rares) données, vous permettant d'ajuster les prévisions et les hypothèses pour déterminer avec précision la valeur intrinsèque d'Ultragenyx Pharmaceutical Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 271.0 | 351.4 | 363.3 | 434.2 | 560.2 | 674.5 | 812.0 | 977.7 | 1,177.1 | 1,417.1 |
| Revenue Growth, % | 0 | 29.66 | 3.39 | 19.52 | 29.01 | 20.39 | 20.39 | 20.39 | 20.39 | 20.39 |
| EBITDA | -139.8 | -410.3 | -640.5 | -516.5 | -469.0 | -587.2 | -707.0 | -851.2 | -1,024.7 | -1,233.7 |
| EBITDA, % | -51.58 | -116.77 | -176.29 | -118.93 | -83.72 | -87.06 | -87.06 | -87.06 | -87.06 | -87.06 |
| Depreciation | 12.3 | 13.2 | 18.2 | 26.0 | 35.5 | 34.6 | 41.6 | 50.1 | 60.3 | 72.7 |
| Depreciation, % | 4.52 | 3.77 | 5.01 | 5.99 | 6.34 | 5.13 | 5.13 | 5.13 | 5.13 | 5.13 |
| EBIT | -152.1 | -423.6 | -658.7 | -542.5 | -504.5 | -601.9 | -724.6 | -872.4 | -1,050.3 | -1,264.5 |
| EBIT, % | -56.11 | -120.53 | -181.3 | -124.92 | -90.06 | -89.23 | -89.23 | -89.23 | -89.23 | -89.23 |
| Total Cash | 1,212.0 | 999.1 | 896.7 | 577.2 | 610.0 | 674.5 | 812.0 | 977.7 | 1,177.1 | 1,417.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.1 | 28.4 | 40.4 | 73.4 | 121.8 | 89.6 | 107.8 | 129.8 | 156.3 | 188.2 |
| Account Receivables, % | 8.52 | 8.09 | 11.13 | 16.9 | 21.74 | 13.28 | 13.28 | 13.28 | 13.28 | 13.28 |
| Inventories | 13.0 | 16.2 | 26.8 | 34.0 | 45.0 | 44.1 | 53.0 | 63.9 | 76.9 | 92.6 |
| Inventories, % | 4.81 | 4.62 | 7.37 | 7.82 | 8.03 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 |
| Accounts Payable | 12.9 | 17.1 | 43.3 | 42.1 | 38.8 | 51.5 | 62.0 | 74.6 | 89.9 | 108.2 |
| Accounts Payable, % | 4.77 | 4.88 | 11.91 | 9.7 | 6.92 | 7.63 | 7.63 | 7.63 | 7.63 | 7.63 |
| Capital Expenditure | -43.9 | -73.1 | -146.1 | -46.8 | -7.5 | -120.5 | -145.1 | -174.7 | -210.3 | -253.2 |
| Capital Expenditure, % | -16.2 | -20.8 | -40.22 | -10.77 | -1.34 | -17.86 | -17.86 | -17.86 | -17.86 | -17.86 |
| Tax Rate, % | -0.28137 | -0.28137 | -0.28137 | -0.28137 | -0.28137 | -0.28137 | -0.28137 | -0.28137 | -0.28137 | -0.28137 |
| EBITAT | -153.1 | -424.5 | -664.1 | -540.8 | -506.0 | -601.5 | -724.2 | -871.9 | -1,049.7 | -1,263.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -207.9 | -488.7 | -788.4 | -602.9 | -540.7 | -641.5 | -844.4 | -1,016.6 | -1,223.9 | -1,473.5 |
| WACC, % | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 | 8.43 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3,975.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -1,503 | |||||||||
| Terminal Value | -23,365 | |||||||||
| Present Terminal Value | -15,587 | |||||||||
| Enterprise Value | -19,563 | |||||||||
| Net Debt | -163 | |||||||||
| Equity Value | -19,399 | |||||||||
| Diluted Shares Outstanding, MM | 91 | |||||||||
| Equity Value Per Share | -214.27 |
What You Will Receive
- Comprehensive Financial Model: Ultragenyx’s actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other critical factors.
- Real-Time Calculations: Instant updates allow you to view results as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling ongoing use for in-depth forecasts.
Key Features
- Comprehensive Financial Data: Access reliable historical data and future forecasts specific to Ultragenyx Pharmaceutical Inc. (RARE).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries to help visualize your valuation findings.
- Designed for All Levels: An easy-to-navigate structure tailored for investors, financial officers, and consultants.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Ultragenyx Pharmaceutical Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the results and utilize them for your investment decisions.
Why Choose Ultragenyx Pharmaceutical Inc. (RARE) Calculator?
- Comprehensive Analysis: Incorporates DCF, WACC, and key financial ratios all in one tool.
- Flexible Inputs: Modify the yellow-highlighted cells to explore different financial scenarios.
- In-Depth Evaluations: Automatically computes Ultragenyx’s intrinsic value and Net Present Value.
- Integrated Data: Historical and projected data provide reliable starting points for analysis.
- Expert-Level Quality: Perfect for financial analysts, investors, and pharmaceutical consultants.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for assessing Ultragenyx Pharmaceutical Inc. (RARE) stock.
- Biotech Analysts: Evaluate various valuation scenarios to inform investment strategies in the biotech sector.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Ultragenyx Pharmaceutical Inc. (RARE).
- Students and Educators: Utilize real-world data to enhance learning in financial modeling and biotech valuation.
- Pharmaceutical Enthusiasts: Gain insights into how companies like Ultragenyx Pharmaceutical Inc. (RARE) are valued within the market.
What the Template Contains
- Preloaded RARE Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.